|Date & Time||27-28 April 2022|
|Address||The Tower Hotel,
St Katherine's Way
In 2021 the life science industry witnessed rapid precision medicine progress led by increased understanding of disease heterogeneity and diagnostic innovation. 12th Clinical Biomarker & CDx Europe Summit ensures you’re in the room alongside the biomarker & diagnostic community to address regulatory changes, exchange novel ideas, gather lessons learned and develop new partnerships at a pivotal moment for precision medicine progress in Europe.
The event aims to:
- Advance Innovative Biomarker Discovery and Development through improvements in non-invasive testing, optimising biomarker translation, the development of robust clinically validated assays and leveraging multi-omic analyses for effectively identifying patient populations with superior efficacy and clinical outcomes.
- Define Market-Leading Drug-Dx Co-Development & Commercialisation Strategies by forging strong collaborations with industry partners, creating awareness for new biomarker implementation, synchronizing drug-dx regulatory approval and market introduction and confidently navigating the nuanced European reimbursement landscape.
- Gain Clarity from European & Global Regulatory Expectations by gathering as an industry to address IVDR’s impacts on clinical, CDx and precision pipeline decision making, changing UK IVD regulation, developing biomarkers providing a clear path forward with regulatory agencies and US, EU & APAC market differences for launching biomarker-driven drug programs.
Make sure you catch Emanuela Oldoni, EATRIS Scientific Program Manager, who will be speaking on 28 April at 10:00 CEST. Her talk is titled: “EATRIS-Plus: The Development of a Multi-Omic Tool Box for Performing High-Quality Research in Personalised Medicine“.
The event is free to attend for all drug developers, academics and researchers. Find out more here.